The importance of an ETEC vaccine
An ETEC vaccine would have a significant impact on global health.
Positive results from our on-going and finished studies are accelerating the development of our tailor-made vaccine presentation for infants in low-to middle income countries where ETVAX® potentially could save hundreds of thousands of lives per year and prevent immense physical suffering and malnutrition due to repeated bouts of illness. The recurring episodes of diarrhoea are known to have a detrimental effect on poverty in ETEC-endemic countries.
ETVAX® will also prevent long-term gastrointestinal syndromes due to diarrhoeal infections following travel, saving millions of well-deserved holiday trips and reducing the disease burden of military and health workers deployed in ETEC-endemic areas.
New vaccines are critical to combat antimicrobial resistance, believed to be one of the biggest global health threats in the future.
ETVAX® is a multivalent oral vaccine that contains 4 different inactivated strains expressing the most prevalent ETEC colonization factors (CFs), i.e. CFA/I, CS3, CS5 and CS6 plus the hybrid protein LCTBA and a mucosal adjuvant, i.e. a double mutant of LT (dmLT).
The vaccine composition offers two potential lines of defense. It prevents adhesion and colonization of ETEC bacteria in the intestine and it induces antibodies that neutralize the heat-labile toxin (LT) produced by the bacteria.
We are on the right path
ETVAX® has demonstrated an excellent safety profile and exceeded expectations for immunogenicity in the completed and on-going studies.
Another proof that we are on the right path and that our vaccine is of very high standard is that we are supported by PATH, an important product development partner of Bill and Melinda Gates Foundation, and the EU Research and Innovation programme, Horizon2020.
In June 2018 during WHO’s 5th Product Development for Vaccines Advisory Committee meeting, ETVAX® was rated by independent scientists as the most advanced ETEC vaccine candidate in the world.